Navigation Links
Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
Date:1/28/2009

continues to build sales momentum and integrate the endovascular business.

Royalty income increased 5% to $6.8 million in the second quarter of fiscal 2009 compared to $6.5 million in the comparable prior fiscal year period. Royalty income in the second quarter of fiscal 2009 included $5.4 million in Angio-Seal(TM) royalties and $1.4 million in royalties from Orthovita, Inc. (Nasdaq: VITA). Although Angio-Seal unit sales exceeded the Company's expectations, royalties were flat with the comparable quarter of the prior fiscal year due to the negative impact of foreign currency exchange of approximately $200,000. The Company had previously assumed a U.S. Dollar to the Euro exchange rate of 1.44 for the second quarter period, but the average actual exchange rate was approximately 1.32. Royalties from the Company's co-developed products with Orthovita increased 28% over the prior fiscal year period due to the recent successful introduction of the new VITOSS(R) Bioactive Foam products, as well as continuing sales of existing VITOSS(R) FOAM products by Orthovita in the end-user marketplace.

Earnings Per Share. Second quarter diluted earnings per share of $0.44 represented an increase of 110% when compared with the $0.21 diluted earnings per share for the same period in fiscal 2008.

Diluted earnings per share exceeded the high end of the Company's previous guidance range of $0.40 to $0.42 primarily due to lower than anticipated operating costs and expenses of approximately $425,000, or $0.03 per share tax effected, which was in-turn offset by lower than anticipated Angio-Seal royalty income of approximately $200,000, or $0.01 per share tax effected, due to the adverse impact of foreign currency fluctuations. The variance in operating costs and expenses was primarily due to a $445,000, tax effected, favorable ma
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
2. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
3. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
4. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
5. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
6. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
7. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
8. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
9. GEN Reports on Growing Reliance on Microfluidics Technology
10. Novozymes Reports Strong 2008 Results
11. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... December 12, 2014 Clarassance, a privately ... its new name: Therabron Therapeutics , Inc. The ... bronchioles (a type of structure in the lungs similar ... mission to develop novel protein therapeutics for the treatment ... decided to change the name to mark the company's ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Production Efficiency and Manage Quality at New LIFE Nutrition ... Honeywell (NYSE: HON ) today announced that ... global manufacturer of healthcare products, to provide process control ... nutrition and infusion therapy solutions. The Leading Infusion Factory ...
... 27 Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE ... Vice President of Research and Development, will be presenting pre-clinical ... Meeting of the American Society of Gene Therapy, which is ... Diego, CA, from Wednesday, May 27th through to Saturday, May ...
... MONICA, Calif., May 27 Cord Blood America, Inc. (OTC ... company ( http://www.cordblood-america.com ) focused ... families nationwide and internationally, said today that it has reduced ... the first five months of 2009. "On April 6th, ...
Cached Biology Technology:Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 2Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 4Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy 2Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy 3Cord Blood America Says Debt Reduced $4.194 Million in 2009 2
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... the first study of its kind, researchers at Queens ... that low socioeconomic status (SES) and maternal gestational diabetes ... deficit hyperactivity disorder (ADHD) in six year olds. The ... Archives of Pediatrics and Adolescent Medicine , one ...
... of a microRNA promotes progressive muscle deterioration in a ... a study published online on January 2 in the ... As DMD patients age, their damaged muscle cells ... fibrosis is partly induced by the growth factor TGF-beta, ...
... Millbrook, N.Y. -- On January 2nd, WAMC Northeast Public Radio ... new radio show called Earth Wise: A look at our ... among radio listeners, with a focus on raising awareness about ... segments will air Monday through Friday at 11:10 AM and ...
Cached Biology News:Gestational diabetes and low socioeconomic status raise risk of ADHD in children 2A firmer understanding of muscle fibrosis 2Cary Institute and WAMC debut new environment radio show 2
CKB Antibody (N-term) Antigen: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected within aa 1~100 of human CKB. Molecular Weight: 42644 Da...
...
The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
... polyacrylamide gel electrophoresis (2D-PAGE) with biological mass ... technology platform for proteomic analysis. 2D-PAGE gels ... limited only in the dynamic range and ... Quantitative image based analysis of separated proteins ...
Biology Products: